Diagnostic accuracy of transrectal elastosonography (TRES) imaging for the diagnosis of prostate cancer

TY - JOUR

T1 - Diagnostic accuracy of transrectal elastosonography (TRES) imaging for the diagnosis of prostate cancer

T2 - A systematic review and meta-analysis

A1 - Aboumarzouk,Omar M.

A1 - Ogston,Simon

A1 - Huang,Zhihong

A1 - Evans,Andrew

A1 - Melzer,Andreas

A1 - Stolzenberg,Jen-Uwe

A1 - Nabi,Ghulum

AU - Aboumarzouk,Omar M.

AU - Ogston,Simon

AU - Huang,Zhihong

AU - Evans,Andrew

AU - Melzer,Andreas

AU - Stolzenberg,Jen-Uwe

AU - Nabi,Ghulum

PY - 2012/3/30

Y1 - 2012/3/30

N2 - What's known on the subject? and What does the study add? Cancer tissue is stiffer than normal tissue, a fact known for many years. This has been measured using ultrasound (US) technology and is termed as elastosonography (ES). There have been reports of this technique being used in the detection of prostate cancer; however, no definite guidelines for its clinical application exist. The present review, for the first time synthesises published data of transrectal ES (TRES) using diagnostic review methodology. TRES increases prostate cancer detection as compared with grey-scale US. Also, the study highlights limitations and strengths of data in this area and includes recommendations for future research. To assess the diagnostic performance of transrectal elastosonography (TRES) for the detection of prostate cancer. Two reviewers independently extracted the data from each study. Quality was assessed with a validated quality assessment tool for diagnostic accuracy studies. Diagnostic accuracy of TRES in relation to current standard references (transrectal ultrasonography [TRUS] biopsies and histopathology of radical prostatectomy [RP] specimens) was estimated. A bivariate random effects model was used to obtain sensitivity and specificity values. Hierarchical summary receiver operating characteristic (HSROC) were calculated. In all, 16 studies (2278 patients) were included in the review. Using histopathology of the RP specimen as reference standard, the pooled data of four studies showed that the sensitivity of TRES ranged between 0.71 to 0.82 and the specificity ranged between 0.60 to 0.95 (pooled diagnostic odds ratio [DOR] 19.6; 95% confidence interval [CI] 7.7-50.03). The sensitivity varied from 0.26 to 0.87 and specificity varied from 0.17 to 0.76 (pooled DOR 2.141; 95% CI 0.525 to -8.737) using TRUS biopsies (minimum of 10) as a reference standard. The quality of most studies was modest. SROC estimated 0.8653 area under the curve predicting high chances of detecting prostate cancer. There were no health economics or health-related quality of life of the participants reported in the studies and all the studies used compressional technique with no reported standardisation. The TRES technique appears to improve the detection of prostate cancer compared with systematic biopsy and shows a good accuracy in comparison with histopathology of the RP specimen. However, studies lacked standardisation of the technique, had poor quality of reporting and a large variation in the outcomes based on the reference standards and techniques used. © 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL.

AB - What's known on the subject? and What does the study add? Cancer tissue is stiffer than normal tissue, a fact known for many years. This has been measured using ultrasound (US) technology and is termed as elastosonography (ES). There have been reports of this technique being used in the detection of prostate cancer; however, no definite guidelines for its clinical application exist. The present review, for the first time synthesises published data of transrectal ES (TRES) using diagnostic review methodology. TRES increases prostate cancer detection as compared with grey-scale US. Also, the study highlights limitations and strengths of data in this area and includes recommendations for future research. To assess the diagnostic performance of transrectal elastosonography (TRES) for the detection of prostate cancer. Two reviewers independently extracted the data from each study. Quality was assessed with a validated quality assessment tool for diagnostic accuracy studies. Diagnostic accuracy of TRES in relation to current standard references (transrectal ultrasonography [TRUS] biopsies and histopathology of radical prostatectomy [RP] specimens) was estimated. A bivariate random effects model was used to obtain sensitivity and specificity values. Hierarchical summary receiver operating characteristic (HSROC) were calculated. In all, 16 studies (2278 patients) were included in the review. Using histopathology of the RP specimen as reference standard, the pooled data of four studies showed that the sensitivity of TRES ranged between 0.71 to 0.82 and the specificity ranged between 0.60 to 0.95 (pooled diagnostic odds ratio [DOR] 19.6; 95% confidence interval [CI] 7.7-50.03). The sensitivity varied from 0.26 to 0.87 and specificity varied from 0.17 to 0.76 (pooled DOR 2.141; 95% CI 0.525 to -8.737) using TRUS biopsies (minimum of 10) as a reference standard. The quality of most studies was modest. SROC estimated 0.8653 area under the curve predicting high chances of detecting prostate cancer. There were no health economics or health-related quality of life of the participants reported in the studies and all the studies used compressional technique with no reported standardisation. The TRES technique appears to improve the detection of prostate cancer compared with systematic biopsy and shows a good accuracy in comparison with histopathology of the RP specimen. However, studies lacked standardisation of the technique, had poor quality of reporting and a large variation in the outcomes based on the reference standards and techniques used. © 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL.

U2 - 10.1111/j.1464-410X.2012.11106.x

DO - 10.1111/j.1464-410X.2012.11106.x

M1 - Article

JO - BJU International

JF - BJU International

SN - 1464-4096

ER -